Successful Cord Blood Transplantation in a Werner Syndrome Patient with High-risk Myelodysplastic Syndrome

Werner syndrome (WS) confers a high risk of the development of neoplasias, including hematological malignancies, and curative treatment for these malignancies is difficult to achieve. A 44-year-old man with myelodysplastic syndrome was admitted to our hospital. He was diagnosed with mutation-proven...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Kiyohito, Tasaka, Taizo, Kondo, Toshinori, Ishikawa, Yuichi, Goto, Makoto, Matsuhashi, Yoshiko, Sadahira, Yoshito, Sugihara, Takashi, Wada, Hideho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367075/
https://www.ncbi.nlm.nih.gov/pubmed/30146558
http://dx.doi.org/10.2169/internalmedicine.0317-17
Descripción
Sumario:Werner syndrome (WS) confers a high risk of the development of neoplasias, including hematological malignancies, and curative treatment for these malignancies is difficult to achieve. A 44-year-old man with myelodysplastic syndrome was admitted to our hospital. He was diagnosed with mutation-proven WS. He underwent cord blood transplantation (CBT) following fludarabine, busulfan, and melphalan administration. A chimerism analysis of his marrow blood on day 62 showed a donor pattern ＞95%, which confirmed engraftment. The patient lived for 15 months while maintaining remission of MDS without treatment-related toxicity. Our case shows that CBT can be a treatment modality for WS patients with hematological malignancies.

Ejemplares similares